Gene: PRDM14

63978
PFM11
PR/SET domain 14
protein-coding
8q13.3
Ensembl:ENSG00000147596 MIM:611781 Vega:OTTHUMG00000150495 UniprotKB:Q9GZV8
NC_000008.11
SNP Mapped
1   ANCO-SNPs
AD
0   
NA (AD)  NA (ND)   (Frontal_Cortex)
8.421e-1 (AD)  7.199e-1 (ND)

ANCO-SNPs

SNP ID Position Alleles Trait Variation Type
rs16936661chr8:70058383 (GRCh38.p7)T>Calcohol dependenceSNV(Single Nucleotide Variation)

DNA Methylation

There is no related methylation information for this gene.

Gene Expression in Different Tissues

Temporal and Spatial Expressions (BrainSpan)

Footnote:
SC: sub-cortical regions; SM: sensory-motor regions; FC: frontal cortex; and TP: temporal-parietal cortex
ST1: fetal (13 - 26 postconception weeks), ST2: early infancy to late childhood (4 months to 11 years), and ST3: adolescence to adulthood (13 - 23 years)
The bar shown representes average value of the expressions.

Top Co-expressed Genes in Brain-Frontal Cortex (BA9) (GTEx v7)

Top 10 positively co-expressed genes

Gene Symbol Pearson Correlation Coefficient
OR56A40.958
PRAMEF170.957
TAS2R410.951
OR10K10.947
OR9Q20.94
TAS2R300.929
MTRNR2L50.929
POU5F20.925
OR2A140.917
TMEM2470.915

Top 10 negatively co-expressed genes

Gene Symbol Pearson Correlation Coefficient
CENPH-0.336
HDDC3-0.316
NPM3-0.312
CCL27-0.291
CHEK1-0.289
FAM207A-0.288
METTL2A-0.284
B9D2-0.28
NUDT6-0.278
WDR53-0.277

Drugs/Compounds

    There is no DrugBank record for this gene !

ID Drug Name Action PubMed
C4591794-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide"[NOG protein co-treated with belinostat co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PRDM14 mRNA"27188386
C4591794-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide"[NOG protein co-treated with entinostat co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PRDM14 mRNA"27188386
C4591794-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide"[NOG protein co-treated with panobinostat co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PRDM14 mRNA"27188386
C4591794-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide"[NOG protein co-treated with Phenylmercuric Acetate co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of PRDM14 mRNA"27188386
C516138(6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine"[NOG protein co-treated with belinostat co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PRDM14 mRNA"27188386
C516138(6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine"[NOG protein co-treated with entinostat co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PRDM14 mRNA"27188386
C516138(6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine"[NOG protein co-treated with panobinostat co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PRDM14 mRNA"27188386
C516138(6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine"[NOG protein co-treated with Phenylmercuric Acetate co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of PRDM14 mRNA"27188386
D000082AcetaminophenAcetaminophen results in increased expression of PRDM14 mRNA26690555
C015001arsenitearsenite results in increased methylation of PRDM14 promoter23974009
C487081belinostatbelinostat results in increased expression of PRDM14 mRNA26272509
C487081belinostat"[NOG protein co-treated with belinostat co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PRDM14 mRNA"27188386
C006780bisphenol Abisphenol A results in increased expression of PRDM14 mRNA19371625
C014476diethyl maleatediethyl maleate results in decreased expression of PRDM14 mRNA25270620
C118739entinostatentinostat results in increased expression of PRDM14 mRNA26272509
C118739entinostat"[NOG protein co-treated with entinostat co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PRDM14 mRNA"27188386
D015025ZearalenoneZearalenone results in increased expression of PRDM14 mRNA19371625
D004397FonofosFonofos results in increased methylation of PRDM14 promoter22847954
C008261lead acetatelead acetate results in decreased expression of PRDM14 mRNA25270620
C004925methylmercuric chloridemethylmercuric chloride results in increased expression of PRDM14 mRNA28001369
D008770MethylnitrosoureaMethylnitrosourea results in decreased expression of PRDM14 mRNA25270620
C496932panobinostat"[NOG protein co-treated with panobinostat co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PRDM14 mRNA"27188386
C496932panobinostatpanobinostat results in increased expression of PRDM14 mRNA26272509
D010278ParathionParathion results in increased methylation of PRDM14 promoter22847954
D010662Phenylmercuric Acetate"[NOG protein co-treated with Phenylmercuric Acetate co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of PRDM14 mRNA"27188386
D010662Phenylmercuric AcetatePhenylmercuric Acetate results in decreased expression of PRDM14 mRNA26272509
C006253pirinixic acidpirinixic acid results in decreased expression of PRDM14 mRNA25270620
D010936Plant ExtractsPlant Extracts results in decreased expression of PRDM14 mRNA23557933
C012568terbufosterbufos results in increased methylation of PRDM14 promoter22847954
C012589trichostatin Atrichostatin A results in decreased expression of PRDM14 mRNA24935251
D014635Valproic AcidValproic Acid results in increased methylation of PRDM14 gene29154799

GO/Pathway

GO ID GO Term Qualifier Evidence PubMed
GO:0000977RNA polymerase II regulatory region sequence-specific DNA binding-IBA21873635  
GO:0000977RNA polymerase II regulatory region sequence-specific DNA binding-IEA-  
GO:0000981RNA polymerase II transcription factor activity, sequence-specific DNA binding-ISA-  
GO:0003700DNA-binding transcription factor activity-IBA21873635  
GO:0003723RNA binding-IEA-  
GO:0005515protein binding-IPI21516116  23088713  25416956  25910212  26871637  27281218  
GO:0008168methyltransferase activity-IEA-  
GO:0031490chromatin DNA binding-IBA21873635  
GO:0031490chromatin DNA binding-IEA-  
GO:0043565sequence-specific DNA binding-IBA21873635  
GO:0046872metal ion binding-IEA-  
GO ID GO Term Qualifier Evidence PubMed
GO:0000122negative regulation of transcription by RNA polymerase II-IBA21873635  
GO:0000122negative regulation of transcription by RNA polymerase II-IEA-  
GO:0000902cell morphogenesis-IEA-  
GO:0001708cell fate specification-IEA-  
GO:0001827inner cell mass cell fate commitment-IEA-  
GO:0006351transcription, DNA-templated-IEA-  
GO:0007281germ cell development-IEA-  
GO:0007566embryo implantation-IEA-  
GO:0009566fertilization-IEA-  
GO:0022008neurogenesis-IBA21873635  
GO:0030718germ-line stem cell population maintenance-IEA-  
GO:0034972histone H3-R26 methylation-IBA21873635  
GO:0034972histone H3-R26 methylation-IEA-  
GO:0035019somatic stem cell population maintenance-TAS-  
GO:0040037negative regulation of fibroblast growth factor receptor signaling pathway-IEA-  
GO:0044030regulation of DNA methylation-IEA-  
GO:0048873homeostasis of number of cells within a tissue-IEA-  
GO:0060817inactivation of paternal X chromosome-IEA-  
GO:1902093positive regulation of flagellated sperm motility-IEA-  
GO:1902459positive regulation of stem cell population maintenance-IEA-  
GO ID GO Term Qualifier Evidence PubMed
GO:0005634nucleus-IBA21873635  
GO:0005654nucleoplasm-IDA-  
GO:0005654nucleoplasm-TAS-  
KEGG ID KEGG Term
Reactome ID Reactome Term Evidence
R-HSA-1266738Developmental BiologyTAS
R-HSA-452723Transcriptional regulation of pluripotent stem cellsTAS

Interactions (STRING v10.5, Interaction Score >= 0.400)

Publications (Co-occurrence of gene symbol strings and ANCO-Dependence terms)

PMID Title (Year) Author Journal